Can Retatrutide Get Rid of Gyno? The Evidence

Retatrutide is an investigational triple hormone receptor agonist currently available only within authorised clinical trials, with no marketing authorisation in the UK or elsewhere. Questions about whether retatrutide can get rid of gyno (gynaecomastia) are understandable, given interest in its effects on body composition, but no published trial has examined this as an outcome. This article explains what retatrutide is, what causes gynaecomastia, what the clinical evidence does and does not show, and where to seek appropriate NHS assessment and treatment for gynaecomastia.

What is retatrutide and what is its current status in the UK?

Retatrutide is an investigational triple hormone receptor agonist with no UK marketing authorisation, available only to participants in authorised clinical trials; it cannot be legally prescribed or supplied outside a formal research setting.

Retatrutide holds no marketing authorisation in the UK or anywhere else, and it is currently available only to participants enrolled in authorised clinical trials.^[1] It is an investigational medicine being studied as a potential treatment for obesity and related metabolic conditions. Unlike tirzepatide (Mounjaro) or semaglutide (Wegovy, Ozempic), retatrutide cannot be prescribed, dispensed or legally supplied outside of a formal research setting.

Retatrutide works by activating three hormone receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple agonist mechanism distinguishes it from currently authorised medicines and is the subject of ongoing investigation in clinical trials, including the TRIUMPH and TRANSCEND programmes. A Phase 2 trial in adults with obesity, published in the New England Journal of Medicine in 2023 (Jastreboff et al.), provided the primary evidence base for its continued development.

Because retatrutide has no UK marketing authorisation, the Medicines and Healthcare products Regulatory Agency (MHRA) has not evaluated it for safety, quality or efficacy to the standard required for routine clinical use. Any product sold online and described as retatrutide is not a licensed medicine and may be falsified or harmful. The MHRA has published guidance on the risks of buying medicines online, which is available at gov.uk/guidance/buying-medicines-online. If you are interested in licensed weight-management treatments, a GP can discuss options that are currently authorised and available through appropriate clinical pathways.

What causes gynaecomastia and what treatments does the NHS offer?

Gynaecomastia is caused by an imbalance between oestrogen and androgen activity in breast tissue; NHS management includes addressing causative medicines, off-label hormonal treatments in specialist settings, and surgery where conservative measures have failed.

Gynaecomastia is the enlargement of breast tissue in males, caused by an imbalance between oestrogen and androgen activity in breast tissue, rather than by excess fat alone. It is a common and usually benign condition that can affect males at any age, including newborns, adolescents and older men. It is distinct from pseudogynaecomastia, which refers to fatty tissue accumulation in the chest without true glandular enlargement.

Common causes include hormonal changes during puberty, certain medicines (such as anabolic steroids, some antipsychotics, spironolactone and some antihypertensives), liver disease, hypogonadism and, less commonly, testicular or adrenal tumours.^[12][11] In many adolescent cases, the condition resolves without treatment within one to two years.^[11][10]

A GP will typically take a full medication history, examine the chest and arrange blood tests to assess hormone levels and rule out underlying causes. Initial investigations may include liver function tests, thyroid function tests, testosterone, LH, FSH, oestradiol, beta-hCG and prolactin, alongside examination for testicular abnormalities.^[11]

Certain features should prompt urgent assessment: a unilateral hard or irregular breast mass, nipple discharge or skin changes (particularly in men aged 50 or over), or an associated testicular mass. These may warrant urgent referral to a breast clinic or endocrinology, in line with NICE guidance on suspected cancer (NG12). Patients with any of these features should contact their GP promptly rather than waiting.

NHS management depends on the underlying cause. Where a causative medicine is identified, switching or stopping it may be sufficient. Hormonal treatments such as tamoxifen are sometimes used off-label in specialist settings for early or painful gynaecomastia; aromatase inhibitors such as anastrozole are used less commonly and with more limited evidence.^[14][15] Surgical reduction (mastectomy or liposuction) is available on the NHS in cases causing significant psychological distress or where conservative measures have failed, though access varies by Integrated Care Board (ICB). Patients concerned about gynaecomastia should speak to their GP in the first instance, who can arrange appropriate investigation and referral if needed.

Has any clinical trial looked at retatrutide and gynaecomastia?

No published clinical trial has examined retatrutide's effect on gynaecomastia; existing trials focus on weight reduction, glycaemic control and cardiovascular risk factors, and none have reported findings on breast tissue in men.

No published clinical trial has specifically investigated whether retatrutide reduces or resolves gynaecomastia. The question of whether retatrutide can treat gynaecomastia has not been examined as a primary or secondary endpoint in any trial reported to date. It would therefore be inaccurate and potentially misleading to suggest that retatrutide is a treatment for this condition.

The Phase 2 trial of retatrutide in adults with obesity (Jastreboff et al., New England Journal of Medicine, 2023) examined outcomes including body weight, cardiometabolic markers and tolerability. It did not report on breast tissue composition or gynaecomastia. The Phase 3 TRIUMPH programme (TRIUMPH-1 to TRIUMPH-4) and the TRANSCEND-T2D-1 trial, which has reported in The Lancet, similarly focus on weight reduction, glycaemic control and cardiovascular risk factors in defined populations.^[6][7] None of these trials have published findings relating to gynaecomastia.

It is biologically plausible that significant weight loss in men with obesity-related pseudogynaecomastia (fatty chest tissue rather than true glandular enlargement) could reduce chest size as part of overall fat loss. However, this is not the same as treating true gynaecomastia, which involves glandular tissue that does not respond to weight loss in the same way. Any claim that retatrutide specifically targets or eliminates gynaecomastia goes beyond what the available evidence supports.

What do researchers think about weight-loss drugs and breast tissue in men?

Weight loss may reduce fatty chest tissue in pseudogynaecomastia, but true gynaecomastia involves glandular tissue that does not respond to weight loss, and no evidence links GLP-1, GIP or glucagon receptor agonists to a direct effect on male breast glandular tissue.

Weight loss achieved through any means, including GLP-1 receptor agonist medicines, may reduce the volume of fatty tissue throughout the body, including the chest area. In men with pseudogynaecomastia, where the chest enlargement is primarily due to adipose (fat) tissue rather than glandular proliferation, meaningful weight loss could plausibly reduce chest size. This is a general effect of fat reduction, not a specific action on breast tissue.

True gynaecomastia, by contrast, involves proliferation of glandular ductal tissue driven by hormonal imbalance. This tissue does not regress with weight loss alone, and there is no published evidence that GLP-1, GIP or glucagon receptor agonists have a direct effect on breast glandular tissue in men. No pharmacological mechanism has been identified by which retatrutide or similar medicines would selectively act on male breast glandular tissue, and no authoritative body including NICE or the MHRA has issued guidance linking weight-loss medicines to the treatment of gynaecomastia.

Some researchers have noted that obesity itself can contribute to hormonal imbalance by increasing peripheral conversion of androgens to oestrogens in adipose tissue, which may worsen gynaecomastia in some men.^[9][10] Weight loss could theoretically improve this hormonal environment, but this remains an area of hypothesis rather than established clinical evidence. Men concerned about breast tissue changes should seek assessment from their GP rather than attributing changes to any specific medicine.

What are the known side effects and safety concerns from retatrutide trials?

The most commonly reported adverse events in retatrutide trials are gastrointestinal, including nausea, vomiting, diarrhoea and constipation; its full safety profile is not yet established as it remains investigational.

The safety profile of retatrutide, as reported in published trial data (Jastreboff et al., New England Journal of Medicine, 2023), shares features common to the GLP-1 receptor agonist class, with gastrointestinal effects being the most frequently reported. Nausea, vomiting, diarrhoea and constipation were among the most common adverse events, and these were generally dose-dependent and most prominent during dose escalation.

The UK SmPCs for authorised GLP-1 medicines, including tirzepatide (Mounjaro) and semaglutide (Wegovy), note that acute pancreatitis has been reported, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome.^[18][19] While retatrutide is not yet authorised and has no UK SmPC, its mechanism of action means similar vigilance is appropriate in trial settings. Participants in retatrutide trials are monitored closely for these and other adverse events under the study protocol.

If you are participating in a retatrutide trial and need unscheduled or emergency care, you should inform the treating clinician that you are enrolled in a clinical trial and show your study participant card. This allows clinicians to take your trial medicine into account when making treatment decisions.

Because retatrutide is investigational, its full safety profile is not yet established. Trial participants who experience suspected side effects should report these to the trial team under the study protocol. Suspected adverse reactions to medicines outside of a clinical trial can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Retatrutide trials exclude participants who are pregnant, breastfeeding or planning pregnancy. Women of childbearing potential participating in trials are required to use effective contraception. This reflects the general precautionary approach applied to investigational medicines where reproductive safety data are not yet available. Anyone with concerns about safety in this context should speak directly to their trial team.

Why can't I get retatrutide outside of a clinical trial in the UK?

Retatrutide has no MHRA marketing authorisation, so there is no legal route for a prescriber or pharmacist to supply it outside a clinical trial; products sold online as retatrutide may be counterfeit or harmful.

Retatrutide cannot be obtained outside of an authorised clinical trial in the UK because it has not received a marketing authorisation from the MHRA. Before any medicine can be prescribed, dispensed or sold in the UK for routine clinical use, the MHRA must evaluate evidence of its quality, safety and efficacy. Retatrutide has not completed that regulatory process, and no application for a UK marketing authorisation has been publicly confirmed as submitted or approved. The MHRA's public list of authorised medicines does not include retatrutide.

This means there is no legal route through which a prescriber, pharmacist or clinic can supply retatrutide to a patient outside of a formal research setting, including via private prescription. Any website or clinic offering retatrutide for purchase or as part of a private consultation is not supplying a licensed medicine. Such products may be counterfeit, contaminated or mislabelled, and their use carries serious and unpredictable risks. The MHRA has warned that falsified medicines sold online pose a significant danger to patient safety, and guidance on this is available at gov.uk/guidance/buying-medicines-online.

No timeline for a potential UK marketing authorisation for retatrutide can be given, and it would be speculative to suggest one. If you are interested in weight management support, licensed options do exist and can be discussed with your GP, who can advise on treatments that have been evaluated and authorised for use in the UK. If you believe you have been sold a product described as retatrutide outside of a clinical trial, you should contact your GP and report the matter to the MHRA at gov.uk/report-problem-medicine-medical-device. For non-urgent health queries, NHS 111 can provide guidance.

Scientific References

1. Medicines and Healthcare products Regulatory Agency.
2. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (Jastreboff et al.).
3. Phase 2 Trial of Retatrutide for Obesity (NEJM summary).
4. Triple–Hormone-Receptor Agonist Retatrutide for Obesity (NEJM full text / correspondence).
5. Retatrutide for the treatment of obesity, obstructive sleep apnoea and related conditions (TRIUMPH programme overview, Giblin et al.).
6. Efficacy and safety of retatrutide, a GIP, GLP-1 and glucagon receptor agonist — TRANSCEND-T2D-1 (Bajaj et al.).
7. Efficacy and safety of retatrutide, a GIP, GLP-1 and glucagon receptor agonist — TRANSCEND-T2D-1 (Bajaj et al., PubMed).
8. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist — Phase 2 T2D trial (Rosenstock et al.).
9. Gynecomastia: pathomechanisms and treatment strategies. Hormone Research..
10. Gynecomastia in Infants, Children, and Adolescents. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery..
11. Gynaecomastia. NHS..
12. Drug-induced gynecomastia: an evidence-based review. Expert Opinion on Drug Safety..
13. Suspected cancer: recognition and referral (NG12). NICE..
14. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide (Boccardo et al.). J Clin Oncol..
15. Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review. BMC Medicine..
16. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia. Cancer Chemotherapy and Pharmacology..
17. Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer. Strahlentherapie und Onkologie..
18. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases. MHRA Drug Safety Update..
19. Tirzepatide. BNF — NICE..

Frequently Asked Questions